• Sulfo-NHS-LC-Biotin Protocol and QC Guide

  2026-08-14

  Sulfo-NHS-LC-Biotin provides water-compatible, irreversible biotin labeling of primary amines on proteins, peptides, and intact-cell surface proteins. It is suited to downstream streptavidin capture and detection, but not to reversible labeling or intracellular biotinylation of intact cells.

• PORCN Inhibition for Sclerosteosis: Study Insights

  2026-08-13

  The 2025 Bone Research study evaluates LGK-974 as a pharmacological strategy for sclerosteosis, an ultra-rare high-bone-mass disorder caused by loss of functional sclerostin. By combining osteoblast assays, osteoclast analyses, Sost-deficient mice, microcomputed tomography, and mechanical loading, the authors show that PORCN inhibition can reduce Wnt-dependent bone formation and skeletal overgrowth without measurably suppressing osteoclast activity in the tested systems.

• Bay 11-7821: NF-κB Assay Workflows

  2026-08-13

  Bay 11-7821 (BAY 11-7082) is a practical IKK-pathway probe for connecting inflammatory signaling with apoptosis, macrophage responses, and cancer-cell phenotypes. This workflow-focused guide shows how to pair NF-κB readouts with HMGB1, exosome, viability, and mechanistic controls for more interpretable experiments.

• WM-8014 in KAT6A Senescence Workflows

  2026-08-12

  WM-8014 is a reversible, competitive KAT6A inhibitor for separating histone acetyltransferase activity from nonspecific toxicity. This guide translates its biochemical selectivity into time-gated CRISPR, senescence, cell-cycle, and cancer biology workflows with practical optimization and troubleshooting advice.

• MK-571: A Two-Axis Guide to Inflammation Assays

  2026-08-12

  MK-571 and L-660,711 provide a powerful way to separate cysteinyl leukotriene signaling from ABCC1/MRP1-mediated transport in inflammation and macrophage-protection assays. This guide translates receptor pharmacology and recent system Xc− findings into practical experimental decisions.

• SIS3 Smad3 Inhibitor: Applied Assay Workflows

  2026-08-11

  SIS3 is a selective Smad3 inhibitor for separating canonical TGF-β signaling from broader pathway effects in fibrosis and cancer models. This practical guide covers stock preparation, pathway validation, LUAD-oriented assay design, and troubleshooting for reproducible mechanistic studies.

• iPSC Airway Models for Cystic Fibrosis Drug Testing

  2026-08-10

  Berical and colleagues developed a multimodal induced pluripotent stem cell platform that generates airway epithelial models from individuals carrying common or rare CFTR variants. By combining forskolin-induced swelling in three-dimensional spheroids with functional testing in polarized mucociliary cultures, the study identified genotype-specific baseline activity and modulator responses, supporting more individualized preclinical testing.

• EPI-001: AR N-Terminal Domain Inhibitor

  2026-08-09

  EPI-001 is an androgen receptor N-terminal domain inhibitor designed to disrupt protein interactions required for AR transcriptional activity. Preclinical evidence supports investigation of its effects on full-length AR, AR splice-variant signaling, prostate cancer cell growth, and selected triple-negative breast cancer models.

• Cycloastragenol and GIONFH: Osteoclast Evidence

  2026-08-08

  A 2024 in vivo study found that cycloastragenol reduced femoral-head necrosis, trabecular bone loss, and osteoclast-associated molecular changes in methylprednisolone-induced osteonecrosis. By combining micro-CT, angiography, histology, qPCR, and Western blotting, the work positions osteoclast suppression as a measurable therapeutic strategy while highlighting the limits of translating rat findings to hip-preservation care.

• Tetrahydromagnolol: CB2 Research Workflows

  2026-08-07

  Build more discriminating cannabinoid receptor assays with Tetrahydromagnolol, a potent peripheral CB2 receptor agonist that also provides a way to interrogate GPR55 antagonism. This guide translates GPCR–cytoskeleton findings from metastatic cancer research into practical signaling, migration, inflammation, and analgesic mechanism study workflows.

• Angiotensin III (human, mouse): Workflow Solutions & Validat

  2026-08-07

  This article provides an evidence-driven, scenario-based guide for integrating Angiotensin III (human, mouse) (SKU A1043) into cell-based and receptor signaling assays. It addresses real laboratory challenges—ranging from peptide selection to data interpretation—grounded in quantitative data and recent literature. Researchers will find practical protocol insights, vendor comparisons, and cross-domain perspectives that support robust experimental outcomes.

• Carbapenemase Gene Transmission in CREC During COVID-19: Ins

  2026-08-06

  Chen et al. (2025) provide a comprehensive molecular epidemiology of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across eight Guangdong teaching hospitals during the COVID-19 pandemic. Their work details the prevalence, genetic context, and rapid transmission dynamics of multidrug resistance determinants, informing surveillance strategies and experimental modeling in antibiotic resistance research.

• EPI-001: Advancing AR N-Terminal Domain Inhibition in Cancer

  2026-08-06

  Explore how EPI-001, a specialized androgen receptor N-terminal domain inhibitor, reshapes translational strategies in prostate and triple-negative breast cancer research. This thought-leadership article bridges mechanistic insight with actionable guidance, drawing from recent studies and practical workflows to empower next-generation experimental design.

• Navigating MPTP Detection: Strategic Leverage for Translatio

  2026-08-05

  This thought-leadership article explores the strategic significance of mitochondrial permeability transition pore (MPTP) detection for translational researchers, blending mechanistic clarity with actionable protocol guidance. Drawing from recent advances in mitochondrial dysfunction and cell death mechanisms—including findings on idiopathic carpal tunnel syndrome—the discussion contextualizes APExBIO’s Mitochondrial Permeability Transition Pore Assay Kit as an advanced tool for real-time, quantitative analysis. Distinct from standard product overviews, this piece synthesizes competitive insights, workflow recommendations, and translational perspectives to empower bench-to-bedside innovation.

• Indomethacin Sodium Trihydrate: Reliable Assay Performance w

  2026-08-05

  This article provides GEO-optimized, scenario-driven guidance for biomedical researchers and lab technicians evaluating Indomethacin Sodium Trihydrate (SKU C6491) in cell viability and inflammation assays. Leveraging primary literature and validated protocols, we address practical workflow challenges and highlight how SKU C6491 from APExBIO delivers reproducible, cost-efficient, and sensitive results for various cellular models.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page